Comment | Published:

Gut microbiota and hypertension

Hypertension Research (2019) | Download Citation


Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Yang T, Richards EM, Pepine CJ, Raizada MK. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease. Nat Rev Nephrol. 2018;14:442–56.

  2. 2.

    Onal E, Afsar B, Covic A, Vaziri N, Kanbay M. Gut microbiota and inflammation in chronic kidney disease and its role in the development in cardiovascular disease. Hypertens Res. 2018; advance online publication, 30 November 2018; 10.1038/s41440-018-0144-z.

  3. 3.

    Honour J. The possible involvement of intestinal bacteria in steroidal hypertension. Endocrinology. 1982;110:285–7.

  4. 4.

    Y Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65:1331–40.

  5. 5.

    Galla S, Chakraborty S, Cheng X, Yeo J, Mell B, Zhang H, et al. Disparate effects of antibiotics on hypertension. Physiol Genom. 2018;50:837–45.

  6. 6.

    Engevik MA, Aihara E, Montrose MH, Shull GE, Hassett DJ, Worrell RT. Loss of NHE3 alters gut microbiota composition and influences Bacteroides thetaiotaomicron growth. Am J Physiol Gastrointest Liver Physiol. 2013;305:G697–711.

  7. 7.

    Li XC, Shull GE, Miguel-Qin E, Chen F, Zhuo JL. Role of the Na+/H+exchanger 3 in angiotensin II-induced hypertension in NHE3-deficient mice with transgenic rescue of NHE3 in small intestines. Physiol Rep. 2015;3:pii: e12605

  8. 8.

    Pluznick JL. Microbial short-chain fatty acids and blood pressure regulation. Curr Hypertens Rep. 2017;19:25

  9. 9.

    Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA, et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation. 2004;109:784–9.

  10. 10.

    Subah Packer C. Estrogen protection, oxidized LDL, endothelial dysfunction and vasorelaxation in cardiovascular disease: New insights into a complex issue. Cardiovasc Res. 2007;73:6–7.

  11. 11.

    Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension. 2014;64:897–903.

  12. 12.

    Reijnders D, Goossens GH, Hermes GD, Neis EP, van der Beek CM, Most J, et al. Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: a randomized double-blind placebo-controlled trial. Cell Metab. 2016;24:63–74.

Download references

Author information


  1. Department of Circulation Regulation in Medicine, Saga University, Saga, Japan

    • Jun-ichi Oyama
  2. Department of Cardiovascular Medicine, Saga University, Saga, Japan

    • Koichi Node


  1. Search for Jun-ichi Oyama in:

  2. Search for Koichi Node in:

Conflict of interest

JO belongs to the endowed department of Fukuda Denshi Co, Ltd. KN received remuneration including lecture fees from AstraZeneca, Astellas Pharma Inc, Nippon Boehringer Ingelheim Co, Ltd, Pfizer Inc, MSD K.K., Daiichi Sankyo Company, Ltd, Kowa Pharmaceutical Co, Ltd, Takeda Pharmaceutical Co, Ltd, Novartis Pharmaceuticals Japan, Mitsubishi Tanabe Pharma Corporation, and Dainippon Sumitomo Pharma Co, Ltd. KN also received scholarship funds or donations granted by Astellas Pharma Inc, Nippon Boehringer Ingelheim Co, Ltd, Daiichi Sankyo Company, Ltd, Takeda Pharmaceutical Co, Ltd, Mitsubishi Tanabe Pharma Corporation, and MSD K.K.

Corresponding author

Correspondence to Jun-ichi Oyama.

About this article

Publication history